Sichuan Kelun Pharmaceutical (002422) H2 2024 earnings summary

Executive summary

• Achieved record-high operating results, with revenue of ¥21.81 billion, up 1.67% year-over-year, and net profit attributable to shareholders of ¥2.94 billion, up 19.53% year-over-year.

• Two innovative drugs were approved and launched, completing a strategic innovation transformation.

• Continued optimization of product structure, cost control, and financing structure contributed to profit growth.

Financial highlights

• Revenue: ¥21.81 billion, up 1.67% year-over-year; net profit attributable to shareholders: ¥2.94 billion, up 19.53%.

• Gross margin for infusion products: 60.16%; non-infusion products: 43.91%.

• R&D expenses: ¥2.17 billion, up 11.68% year-over-year, accounting for 9.95% of revenue.

• Cash flow from operations: ¥4.49 billion, down 15.82% year-over-year.

• Total assets: ¥37.32 billion; net assets attributable to shareholders: ¥22.48 billion.

Outlook and guidance

• 2025 focus on innovation, full-staff marketing, saturated production, cost compression, and blue ocean creation.

• Plans to launch over 30 generic drugs and advance more than 10 clinical-stage innovative drugs.

• Continued investment in AI-driven R&D and production efficiency.